Citron's Andrew Left Sees Google Eventually Buying Fitbit

The transcript discusses Fitbit's market challenges and potential as a Medtech company. Andrew Left from Citron Research highlights Fitbit's strategic shift towards Medtech, emphasizing its partnerships with Dexcom and Google. The discussion covers Fitbit's R&D investments compared to competitors like Garmin and Inogen, and the potential for acquisition by tech giants like Google or Apple. The conversation also touches on Fitbit's execution capabilities and market opportunities, particularly in diabetes management. The conclusion suggests a positive future outlook for Fitbit, despite current market skepticism.

What is Andrew Left's year-end price target for Fitbit?

What are the potential positive catalysts mentioned for Fitbit?

What is the significance of the FDA granting approval to Fitbit?

How does Andrew Left compare Fitbit to other companies like Garmin and Inogen?

Why does Andrew Left believe that Google might acquire Fitbit?

What are the risks associated with Fitbit's current market strategy?

What factors does Andrew Left believe will drive consumer demand for Fitbit's technology?